aripiprazole has been researched along with Disruptive, Impulse Control, and Conduct Disorders in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| De Ponti, F; Fusaroli, M; Giunchi, V; Menchetti, M; Poluzzi, E; Raschi, E; Rimondini Giorgini, R | 1 |
| Dawson, J; Dolan, S; Mohan, R; Mohan, T | 1 |
| Forlano, R; Peterson, E | 1 |
| Aguirre, C; Domingo-Echaburu, S; Garcia, M; Hernandez, R; Lertxundi, U; Medrano, J | 1 |
| Ali, M; Das, S; Guruprasad, S; Reddy, B | 1 |
| Abdelhakim, W; Al-Tajali, A; Naguy, A | 1 |
| Challet-Bouju, G; Derkinderen, P; Etcheverrigaray, F; Gaboriau, L; Grall-Bronnec, M; Jolliet, P; Leboucher, J; Perrouin, F; Sauvaget, A; Victorri-Vigneau, C | 1 |
| Carleton, BC; Etminan, M; Guo, M; Procyshyn, RM; Samii, A; Sodhi, M | 1 |
| Mahapatra, A; Sagar, R; Sharma, P | 1 |
| Bastiampillai, T; Cao, CZ; Dhillon, R; Eckert, TG; Tibrewal, P | 1 |
| Hamamura, T; Kodama, M | 1 |
| Bowden-Jones, H; Kitchenham, N; Smith, N | 1 |
| Khemiri, L; Moreira, T; Runeson, L | 1 |
| Carter, WG; Shillcutt, SD | 1 |
2 review(s) available for aripiprazole and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
Hypersexuality induced by Aripiprazole: Two case reports and review of the literature.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Mental Disorders; Sexual Behavior | 2018 |
Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review.
Topics: Adolescent; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Gambling; Humans; Receptors, Dopamine D2; Risk Factors | 2016 |
13 other study(ies) available for aripiprazole and Disruptive, Impulse Control, and Conduct Disorders
| Article | Year |
|---|---|
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Dopamine; Dopamine Agonists; Humans; Hyperphagia; Lurasidone Hydrochloride; Olanzapine; Pharmacovigilance; Quinolones; Receptors, Serotonin; Thiophenes; United States; United States Food and Drug Administration | 2022 |
Aripiprazole and impulse-control disorders in high-risk patients.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Middle Aged; Risk; Schizophrenia | 2017 |
Partial dopamine agonist-induced pathological gambling and impulse-control deficit on low-dose aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Gambling; Humans | 2017 |
Aripiprazole and impulse control disorders: higher risk with the intramuscular depot formulation?
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Disruptive, Impulse Control, and Conduct Disorders; Drug Compounding; Female; Humans; Intramuscular Absorption; Male; Middle Aged; Pharmacovigilance; Risk Factors; Young Adult | 2018 |
Two Adolescent Cases of Psychotropic-Related Nonaffective Oniomania.
Topics: Adolescent; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Methylphenidate; Psychotropic Drugs | 2018 |
Aripiprazole: impulse control disorders. Pathological gambling.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Suicide | 2016 |
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzothiazoles; Canada; Case-Control Studies; Cohort Studies; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Drug-Related Side Effects and Adverse Reactions; Female; Gambling; Humans; Indoles; Male; Middle Aged; Pramipexole | 2017 |
Aripiprazole induced Impulse Control Disorders: Where do we stand?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Middle Aged; Psychotic Disorders; Schizophrenia; Young Adult | 2016 |
Aripiprazole and Impulse-Control Disorders: A Recent FDA Warning and a Case Report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Schizophrenia; United States; United States Food and Drug Administration | 2017 |
Aripiprazole-induced behavioural disturbance related to impulse control in a clinical setting.
Topics: Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2010 |
Pathological gambling and the treatment of psychosis with aripiprazole: case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Disruptive, Impulse Control, and Conduct Disorders; Gambling; Humans; Male; Piperazines; Quinolones; Recurrence; Schizophrenia | 2011 |
Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain Injuries; Disruptive, Impulse Control, and Conduct Disorders; Humans; Male; Middle Aged; Piperazines; Quinolones | 2011 |
Aripiprazole augmentation of venlafaxine in the treatment of psychogenic excoriation.
Topics: Antipsychotic Agents; Aripiprazole; Cyclohexanols; Disruptive, Impulse Control, and Conduct Disorders; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Skin; Treatment Outcome; Venlafaxine Hydrochloride | 2006 |